We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+2.02%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$51.6M
Cap. Flow
-$47.1M
Cap. Flow %
-13.85%
Top 10 Hldgs %
92.17%
Holding
22
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$40.9M
2
PRCT icon
Procept Biorobotics
PRCT
+$6.17M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$294M
$75.7M 22.28%
3,379,064
– –
LEGN icon
2
Legend Biotech
LEGN
$3.93B
$66.5M 19.56%
1,629,173
– –
PRCT icon
3
Procept Biorobotics
PRCT
$1.26B
$35.8M 10.54%
863,908
-154,570
-15% -$6.17M
CVRX icon
4
CVRx
CVRX
$78.3M
$32.6M 9.6%
3,495,575
– –
MGTX icon
5
MeiraGTx Holdings
MGTX
$1.17B
$24.4M 7.17%
2,898,550
– –
PTGX icon
6
Protagonist Therapeutics
PTGX
$9.8B
$20.6M 6.08%
2,449,183
– –
XNCR icon
7
Xencor
XNCR
$1.71B
$19.4M 5.72%
748,062
– –
HLTH
8
DELISTED
Cue Health Inc. Common Stock
HLTH
$16.7M 4.91%
5,548,864
– –
FUSN
9
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$11M 3.25%
3,670,516
– –
ACET icon
10
Adicet Bio
ACET
$77.3M
$10.4M 3.05%
45,559
– –
ARWR icon
11
Arrowhead Research
ARWR
$12.1B
$8.18M 2.41%
247,598
-1,013,271
-80% -$40.9M
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.73M 2.27%
1,000,000
– –
VOR icon
13
Vor Biopharma
VOR
$1.38B
$4.28M 1.26%
53,733
– –
NNOX icon
14
Nano X Imaging
NNOX
$73.2M
$2.21M 0.65%
192,429
– –
ALDX icon
15
Aldeyra Therapeutics
ALDX
$86.9M
$2.11M 0.62%
394,834
– –
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$815K 0.24%
281,052
– –
PHGE icon
17
BiomX
PHGE
$1.67M
$725K 0.21%
11,228
– –
PHAS
18
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$283K 0.08%
1,607,044
– –
TCON
19
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$140K 0.04%
4,200
– –
SENS icon
20
Senseonics Holdings Inc
SENS
$409M
$72K 0.02%
2,731
– –
CALC icon
21
CalciMedica
CALC
$20.2M
$47K 0.01%
3,539
– –
GYRE icon
22
Gyre Therapeutics
GYRE
$693M
$34K 0.01%
8,927
– –

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q3 2022 Portfolio in Review

As of Q3 2022, Johnson & Johnson held 22 positions worth $340M, down 13% from $391M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Johnson & Johnson withdrew a net $47.1M in Q3 2022, reducing 2 holdings. Its largest reduction was Arrowhead Research, cutting an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's biggest Q3 2022 reduction was Arrowhead Research, cutting an estimated $40.9M.
  • Johnson & Johnson's ten largest holdings make up 92% of its $340M portfolio in Q3 2022.
  • Johnson & Johnson opened 0 new positions and closed 0 in Q3 2022.
  • Johnson & Johnson's portfolio value fell 13% quarter-over-quarter to $340M.

Based on Johnson & Johnson's 13F filing for Q3 2022, filed 10 Nov 2022.